Home › Companies › Protagonist Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Protagonist Therapeutics, Inc.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore Protagonist Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Protagonist Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Dinesh V. Patel, Ph.D. | 48,714,702 | -- | -- | 7,875,311 | 2,819,234 | Majority: yes |
| Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D. | 45,371,193 | -- | -- | 11,218,820 | 2,819,234 | Majority: yes |
| Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers | 53,412,559 | 3,164,702 | 12,752 | -- | 2,819,234 | Passed |
| Proposal 3: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 | 59,371,487 | 28,221 | 9,539 | -- | -- | Passed |
| Proposal 4: To approve the adoption of the Company's 2026 Equity Incentive Plan | 47,745,562 | 8,826,703 | 17,748 | -- | 2,819,234 | Passed |
Source: Protagonist Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.
Each item below shows how the 361 asset managers that disclosed a Protagonist Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Protagonist Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 7 wordings of this item as funds reported it.
94% Passed · of votes cast
Protagonist Therapeutics, Inc.’s own tally for this item (“Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 53,412,559 for, 3,164,702 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 64,227,057 outstanding shares: 83% for, 5% against (88% of the company cast a for/against vote).
The 360 asset managers below cast 94% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,700,276 | 9 | 0 | 0 | For |
| BlackRock | 7,826,423 | 31,019 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 5,059,053 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 4,779,080 | 0 | 0 | 0 | For |
| Janus Henderson | 3,439,829 | 0 | 0 | 0 | For |
| Invesco | 488,606 | 2,643,454 | 0 | 0 | Against |
| T. Rowe Price | 3,098,730 | 0 | 0 | 0 | For |
| Fidelity | 2,820,431 | 0 | 0 | 0 | For |
| Wellington | 2,703,511 | 0 | 0 | 0 | For |
| State Street | 1,821,691 | 321 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,679,699 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,219,306 | 0 | 0 | 0 | For |
| Charles Schwab | 1,035,967 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 908,483 | 0 | 0 | 0 | For |
| American Century | 873,967 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 835,481 | 0 | 0 | 0 | For |
| Voya | 722,994 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 623,901 | 0 | 0 | 0 | For |
| Northern Trust | 555,144 | 4,088 | 0 | 0 | For |
| Prudential/PGIM | 526,384 | 600 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 516,333 | 0 | 0 | 0 | For |
| Putnam | 452,041 | 0 | 0 | 0 | For |
| Jackson National | 200,104 | 186,952 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 377,236 | 0 | 0 | 0 | For |
Showing the 25 largest of 360 asset managers. See all 360 in the interactive database.
Combines 3 wordings of this item as funds reported it.
84% Passed · of votes cast
Protagonist Therapeutics, Inc.’s own tally for this item (“Proposal 4: To approve the adoption of the Company's 2026 Equity Incentive Plan”): 47,745,562 for, 8,826,703 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 64,227,057 outstanding shares: 74% for, 14% against (88% of the company cast a for/against vote).
The 110 asset managers below cast 91% of the shares they voted on this item FOR (24,760,327 for, 2,450,684 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,179,222 | 17,609 | 0 | 0 | For |
| BlackRock | 5,991,934 | 0 | 0 | 0 | For |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 1,570,687 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,085 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 772,559 | 1,787 | 0 | 0 | For |
| Prudential/PGIM | 481,376 | 7,768 | 0 | 0 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 0 | 412,809 | 0 | 0 | Against |
| Jackson National | 188,307 | 198,749 | 0 | 0 | Against |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 0 | 304,405 | 0 | 0 | Against |
| Legg Mason | 235,216 | 6,209 | 0 | 0 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 6,532 | 172,647 | 0 | 0 | Against |
| Victory Capital | 544 | 161,490 | 0 | 0 | Against |
| Duquesne Family Office LLC | 159,700 | 0 | 0 | 0 | For |
| NEXTBio Capital Management LP | 152,866 | 0 | 0 | 0 | For |
| Equitable | 146,029 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 138,752 | 0 | 0 | Against |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| John Hancock | 51,440 | 73,361 | 0 | 0 | Against |
| TIAA | 118,095 | 0 | 0 | 0 | For |
Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Passed · of votes cast
Protagonist Therapeutics, Inc.’s own tally for this item (“Proposal 3: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026”): 59,371,487 for, 28,221 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 64,227,057 outstanding shares: 92% for, 0.1% against (92% of the company cast a for/against vote).
The 106 asset managers below cast 99.9% of the shares they voted on this item FOR (27,008,763 for, 24,325 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,196,831 | 0 | 0 | 0 | For |
| BlackRock | 5,991,934 | 0 | 0 | 0 | For |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 1,570,687 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,085 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 774,346 | 0 | 0 | 0 | For |
| Prudential/PGIM | 489,144 | 0 | 0 | 0 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 412,809 | 0 | 0 | 0 | For |
| Jackson National | 387,056 | 0 | 0 | 0 | For |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 304,405 | 0 | 0 | 0 | For |
| Legg Mason | 241,425 | 0 | 0 | 0 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 179,179 | 0 | 0 | 0 | For |
| Victory Capital | 162,034 | 0 | 0 | 0 | For |
| Equitable | 146,029 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 138,752 | 0 | 0 | 0 | For |
| Brighthouse | 127,641 | 0 | 9,310 | 0 | For |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| John Hancock | 124,801 | 0 | 0 | 0 | For |
| TIAA | 118,095 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 106,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.
Combines 6 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Protagonist Therapeutics, Inc.’s own tally for this item (“Elect Director: Dinesh V. Patel, Ph.D.”): 48,714,702 for, 7,875,311 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,227,057 outstanding shares: 76% for, 12% withheld (88% of the company cast a for/withheld vote).
The 103 asset managers below cast 100% of the shares they voted on this item FOR (25,050,229 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,196,775 | 0 | 56 | 0 | For |
| BlackRock | 5,991,934 | 0 | 0 | 0 | For |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 1,570,687 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,085 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 773,456 | 0 | 890 | 0 | For |
| Prudential/PGIM | 484,616 | 0 | 4,528 | 0 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 412,809 | 0 | Abstain |
| Jackson National | 188,307 | 0 | 198,749 | 0 | Abstain |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 304,405 | 0 | 0 | 0 | For |
| Legg Mason | 235,216 | 0 | 6,209 | 0 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 172,647 | 0 | 0 | 0 | For |
| Victory Capital | 544 | 0 | 161,490 | 0 | Abstain |
| Equitable | 146,029 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 138,752 | 0 | Abstain |
| Brighthouse | 107,116 | 0 | 29,835 | 0 | For |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| John Hancock | 51,440 | 0 | 73,361 | 0 | Abstain |
| TIAA | 118,095 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 106,616 | 0 | Abstain |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Combines 8 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Protagonist Therapeutics, Inc.’s own tally for this item (“Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D.”): 45,371,193 for, 11,218,820 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 64,227,057 outstanding shares: 71% for, 17% withheld (88% of the company cast a for/withheld vote).
The 103 asset managers below cast 100% of the shares they voted on this item FOR (22,858,131 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,196,754 | 0 | 77 | 0 | For |
| BlackRock | 5,438,131 | 0 | 553,803 | 0 | For |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 1,570,687 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 1,349,085 | 0 | Abstain |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 773,456 | 0 | 890 | 0 | For |
| Prudential/PGIM | 484,616 | 0 | 4,528 | 0 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 412,809 | 0 | Abstain |
| Jackson National | 186,952 | 0 | 200,104 | 0 | Abstain |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 304,405 | 0 | 0 | 0 | For |
| Legg Mason | 235,216 | 0 | 6,209 | 0 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 172,647 | 0 | 0 | 0 | For |
| Victory Capital | 544 | 0 | 161,490 | 0 | Abstain |
| Equitable | 82,788 | 0 | 63,241 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 138,752 | 0 | Abstain |
| Brighthouse | 94,311 | 0 | 42,640 | 0 | For |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| John Hancock | 27,444 | 0 | 97,357 | 0 | Abstain |
| TIAA | 0 | 0 | 118,095 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 106,616 | 0 | Abstain |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
70% fund support · no official result
The 3 asset managers below cast 70% of the shares they voted on this item FOR (97,011 for, 42,227 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Brighthouse | 94,311 | 0 | 0 | 0 | For |
| Empower | 0 | 42,227 | 0 | 0 | Against |
| CLEARWATER INVESTMENT TRUST | 2,700 | 0 | 0 | 0 | For |
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR (13,149 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Franklin Alternative Strategies Funds | 6,532 | 0 | 0 | 0 | For |
| Putnam | 6,532 | 0 | 0 | 0 | For |
| Meeder Funds | 85 | 0 | 0 | 0 | For |
Ranked by the number of Protagonist Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 64,227,057 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 13.55% |
| 2 | BlackRock | 12.23% |
| 3 | RTW INVESTMENTS, LP | 7.88% |
| 4 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 7.44% |
| 5 | Janus Henderson | 5.36% |
| 6 | Invesco | 4.88% |
| 7 | T. Rowe Price | 4.82% |
| 8 | Fidelity | 4.39% |
| 9 | Wellington | 4.21% |
| 10 | State Street | 2.84% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 15.23% | 13F |
| Entities affiliated with BlackRock, Inc. | 13.35% | DEF14A |
| Farallon Capital Management, L.L.C. | 10.02% | 13G |
| Entities affiliated with Farallon Partners, L.L.C. | 9.97% | DEF14A |
| Entities affiliated with The Vanguard Group | 8.43% | DEF14A |
| Vanguard Group | 8.43% | 13F |
| Entities affiliated with RTW Investments, L.P. | 7.88% | DEF14A |
| RTW Investments, LP | 7.88% | 13G |
| Wellington Management | 5.60% | 13F |
| Vanguard Portfolio Management | 5.50% | 13G |
Percentages above are of 64,227,057 shares outstanding, as reported by Protagonist Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Protagonist Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Protagonist Therapeutics, Inc.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 361 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,486 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — the proposal passed with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Protagonist Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.
Protagonist Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).